Endo International plc (ENDP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.57-0.85 (-4.16%)
At close: 4:00 PM EDT

19.57 0.00 (0.00%)
After hours: 5:42 PM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close20.42
Bid19.57 x 100
Ask20.60 x 500
Day's Range19.27 - 20.59
52wk Range12.56 - 63.71
1y Target EstN/A
Market Cap4.36B
P/E Ratio (ttm)-4.48
Avg Vol (3m)6,301,816
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Marketwiredyesterday

    3D Signatures Inc. Introduces Business Advisory Board and Celebrates Recent Listing by Opening Toronto Stock Exchange November 2

    3D Signatures Inc. is pleased to introduce the following internationally renowned senior biotech executives as members of the Company's Business Advisory Board.Jonathan Goodman, Director & CEO, Knight......

  • Endo International Plc breached its 50 day moving average in a Bullish Manner : ENDP-US : October 26, 2016
    Capital Cube2 days ago

    Endo International Plc breached its 50 day moving average in a Bullish Manner : ENDP-US : October 26, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Endo International Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Barrons.com4 days ago

    Valeant Pharmaceuticals: Stay Far Away, JPMorgan Says

    In a report looking ahead to earnings from specialty pharmaceutical companies like Allergan (AGN), and Endo International (ENDP), JPMorgan's Chris Schott and team call Valeant Pharmaceuticals International (VRX) a name to "avoid." They explain why: Ahead of 3Q EPS results, we wanted to share our latest thoughts on our Specialty Pharma group. For names we would own into 3Q, we would highlight Allergan, Endo International and Akorn (AKRX) and would avoid Valeant and Impax Laboratories (IPXL), where we see risk to guidance given the implied steep 2H ramp... Valeant: Remain cautious into a widely expected guidance cut.